We believe that DNA hypermethylation of miR-133a-3p and the miR-133a-3p/MAML1/DNMT3A axis may provide novel therapeutic targets for the treatment of breast cancer, which is also of crucial significance for clinical prevention and diagnosis. This evidence concerns the gene MAML1 and breast carcinoma.